medroxyprogesterone acetate has been researched along with Cardiovascular Diseases in 112 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.57) | 18.7374 |
| 1990's | 20 (17.86) | 18.2507 |
| 2000's | 63 (56.25) | 29.6817 |
| 2010's | 24 (21.43) | 24.3611 |
| 2020's | 1 (0.89) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, GL; Aragaki, AK; Banack, H; Chlebowski, RT; Gass, M; Manson, JE; Prentice, RL; Qi, L; Rossouw, JE; Shadyab, AH; Snively, BM; Wallace, R; Zhao, S | 1 |
| Archer, DF; Hodis, HN; Langer, RD; Lobo, RA; Pickar, JH; Pines, A; Sarrel, PM; Simon, JA; Utian, WH | 1 |
| Bhupathiraju, SN; Grodstein, F; Hu, FB; Manson, JE; Rosner, BA; Stampfer, MJ; Willett, WC | 1 |
| Bahamondes, L; Cursino, K; de Lima, GA; de Nazaré Silva Dos Santos, P; Fernandes, A; Pavin, EJ | 1 |
| Berco, M; Bhavnani, BR; Cecutti, A; Gerulath, A; Woolever, AC | 1 |
| Curb, JD; Manson, JE; Martin, LW; Phillips, L; Stefanick, M; Trevisan, M; Wild, RA; Wu, C | 1 |
| Li, J; Liu, X; Yang, D; Yuan, Z | 1 |
| Arya, R; Cardozo, L; Hamoda, H; McEniery, C; Mittal, M; Narvekar, N; Panay, N; Savvas, M | 1 |
| Bhavnani, BR; Stanczyk, FZ | 1 |
| Simon, JA | 1 |
| Chen, FL; Deng, Y; Jiang, JF; Sun, AJ; Wang, YF; Wang, YP; Xue, W; Zhang, Y; Zheng, TP | 1 |
| Mejía, A; Palacios, S | 1 |
| Dilshad, H; Jamil, S; Khatoon, H; Shoaib, MH; Yousuf, RI | 1 |
| Aragaki, AK; Cauley, JA; Howard, BV; Jiang, X; Johnson, KC; LeBlanc, ES; Manson, JE; Martin, LW; Nudy, M; O'Sullivan, DM; Payne, ME; Robbins, J; Schnatz, PF; Shikany, JM; Stefanick, ML; Williams, M | 1 |
| Hermsmeyer, RK; Kaski, JC; Pohost, GM; Thompson, TL | 1 |
| Blanchette, PL; Cochrane, B; Ko, MG; Limacher, M; Ockene, JK; Ren, H; Robinson, JG; Wallace, R; Wassertheil-Smoller, S | 1 |
| Gram, J; Jespersen, J; Nilas, L; Sidelmann, JJ; Skouby, SO | 1 |
| Ferriani, RA; Franceschini, SA; Lizarelli, PM; Martins, WP; Patta, MC; Soares, GM; Vieira, CS | 1 |
| de Kraker, AT; Kenemans, P; Kroeks, MV; Smolders, RG; van der Mooren, MJ | 1 |
| Canonico, M; Plu-Bureau, G; Scarabin, PY | 1 |
| Callejon, DR; Franceschini, SA; Rios, DR; Toloi, MR | 1 |
| Hitchcock, CL; Kalyan, S; Prior, JC; Pudek, M; Sirrs, S | 1 |
| Weisberg, E | 1 |
| Mikkola, TS; Tikkanen, MJ; Tuomikoski, P; Ylikorkala, O | 1 |
| Brinton, EA; Cedars, MI; Freeman, RG; Harman, SM; Merriam, GR; Naftolin, F; Santoro, N | 1 |
| Sullivan, JL | 1 |
| Pines, A; Sturdee, D | 1 |
| Gupta, RK; Gyawali, P; Jha, B; Poudel, B; Shrestha, R; Sigdel, M; Yadav, BK | 1 |
| Castanho, VS; de Faria, EC; Gidlund, M; Nakamura, R | 1 |
| Buchanan, TA; Jurow, R; Liu, X; Segall-Gutierrez, P; Stanczyk, FZ; Trigo, E; Watanabe, RM; Xiang, AH | 1 |
| Barnhart, KT; Chen, TJ; Chen, YC; Hwang, WT; Liu, Z; Su, IH; Su, TP; Yang, YX | 1 |
| Enserink, M | 1 |
| Graff-Iversen, S; Tonstad, S | 1 |
| Bosch, X | 1 |
| Allum, AR; de Jong, SA; Jones, SD; Manning, PJ; Sutherland, WH | 1 |
| Lemay, A | 1 |
| Bursi, F; Cagnacci, A; Carbonieri, A; Fantini, G; Fortuna, A; Modena, MG; Rossi, R | 1 |
| Blake, JM; Christilaw, J; Collins, JA; Cooper, J; Fedorkow, DM; Fortier, M; Fortin, C; Jolly, EE; Lalonde, AB; Lemay, A; Maxted, JM; O'Grady, K; O'Grady, T; Reid, RL; Smith, TE; Turek, MA | 1 |
| Barnabei, VM; Cauley, JA; Grady, D; Lin, F; Pickar, JH; Stefanick, ML; Stovall, DW; Stuenkel, CA | 1 |
| Fukaya, T; Okatani, Y; Wakatsuki, A | 1 |
| Randal, J | 1 |
| Hendrix, SL | 1 |
| Bots, ML; Dallinga-Thie, GM; Grobbee, DE; Ossewaarde, ME; Rabelink, TJ; van der Schouw, YT; Westerveld, HT | 1 |
| Aktepe, O; Fenkci, S; Fenkci, V; Kurtay, G; Sonmezer, M; Yilmazer, M | 1 |
| Lippert, TH; Mueck, AO; Seeger, H | 1 |
| Ahn, JY; Choi, IS; Han, SH; Jin, DK; Kang, WC; Kim, DS; Kim, HS; Koh, KK; Shin, EK; Yoon, BK | 1 |
| Machens, K; Schmidt-Gollwitzer, K | 1 |
| Welty, FK | 1 |
| Kocjan, T; Prelevic, GM | 1 |
| Lech, MM | 1 |
| Minkin, MJ | 1 |
| Aschenbrenner, DS | 1 |
| Barton, M; Ortmann, J; Traupe, T; Vetter, W | 1 |
| Jassem, J; Senkus-Konefka, E | 1 |
| Chang, TC; Chen, M; Chen, RJ; Cheng, SP; Chow, SN; Lien, YR | 1 |
| Alper, T; Cetinkaya, MB; Kokcu, A; Malatyalioglu, E; Yanik, FF | 1 |
| Merz, WE | 1 |
| Birkhäuser, M; de Geyter, C; Keller, PJ; Luzuy, F | 1 |
| Cerquetani, E; Fini, M; Mercuro, G; Rosano, GM; Vitale, C; Zoncu, S | 1 |
| Artini, PG; Battaglia, C; de Aloysio, D; Mancini, F; Persico, N; Regnani, G; Volpe, A | 1 |
| Ergur, AR; Ertekin, A; Gun, I; Mungen, E; Tutuncu, L; Yergok, YZ | 1 |
| Freedman, DA; Petitti, DB | 1 |
| Anderson, S; Durrington, PN; Gibson, MJ; Heald, A; Kaushal, K; Redpath, M; Selby, PL | 1 |
| Anderson, G; Barad, D; Curb, JD; Howard, BV; Kotchen, J; Kuller, L; Langer, R; Limacher, M; Pettinger, M; Prentice, RL; Stefanick, ML; Wactawski-Wende, J | 1 |
| Anderson, GL; Barad, D; Curb, JD; Howard, BV; Kotchen, J; Kuller, L; Langer, RD; Limacher, M; Pettinger, M; Prentice, RL; Stefanick, ML; Wactawski-Wende, J | 1 |
| Colditz, GA; Grodstein, F; Manson, JE; Stampfer, MJ; Willett, WC | 1 |
| Kuhl, H; Stevenson, J | 1 |
| Shapiro, S | 1 |
| Barad, D; Barnabei, VM; Ko, M; LaCroix, AZ; Manson, JE; Margolis, KL; Prentice, RL; Rossouw, JE; Stefanick, ML; Wu, L | 1 |
| Demircan, S; Kizilkaya, K; Köseoğlu, K; Odabasi, AR; Onur, E; Yüksel, H | 1 |
| Blumenfeld, Z; Boulman, N; Leiba, R; Levy, Y; Linn, R; Shachar, S; Siegler, E | 1 |
| Ausmanas, MK; Haines, CJ; Holinka, CF; Subramaniam, R; Taechakraichana, N; Tian, XW | 1 |
| Goldie, MP | 1 |
| Kaplan, PF; Meendering, JR; Miller, NP; Minson, CT; Torgrimson, BN | 1 |
| Anderson, GL; Aragaki, A; Beresford, SA; Brzyski, R; Chlebowski, RT; Gass, M; Heiss, G; LaCroix, A; Manson, JE; Prentice, RL; Rossouw, J; Stefanick, ML; Wallace, R | 1 |
| Taskinen, MR | 1 |
| Folsom, AR; Heiss, G; Nabulsi, AA; Patsch, W; Szklo, M; White, A; Wu, KK | 1 |
| Oyelola, OO | 1 |
| Frederiksen, MC | 1 |
| Chung, TK; Haines, CJ; Lau, JT; Masarei, JR; Tomlinson, B | 1 |
| Anthony, MS; Cefalu, WT; Clarkson, TB; Jayo, MJ; Martino, MA; Wagner, JD | 1 |
| Bjäörn, M; Ehnholm, C; Kääriänen, J; Lahdenperä, S; Luotola, H; Puolakka, J; Pyörälä, T; Taskinen, MR | 1 |
| Bérubé, S; Bissonnette, F; Fugère, P; Lussier-Cacan, S | 1 |
| Chen, FP; Cherng, WJ; Lee, N; Soong, YK; Wang, CH | 1 |
| Bush, TL; Espeland, MA; Marcovina, SM; Miller, V; Schrott, H; Sherwin, R; Wasilauskas, C; Wood, PD | 1 |
| Anderson, PW; Farmer, M; Kuller, LH; Lawrence, JB; Paul, S; Shah, AS; Walsh, BW; Wild, RA | 1 |
| Modena, MG; Molinari, R; Muia, N; Origliani, G; Rombolà, O; Rossi, R | 1 |
| Chen, FP; Lee, N; Soong, YK | 1 |
| Kneer-Aronoff, C | 1 |
| Jones, KP | 1 |
| Barrett-Connor, E; Cushman, M; Judd, HL; Kessler, C; Legault, C; Sakkinen, PA; Stefanick, ML; Tracy, RP | 1 |
| Abellán Alemán, J; Carbonell Meseguer, LF; Díaz Fernández, J; García Sánchez, FA; Leal Hernández, M; Martínez Selva, JM | 1 |
| Cabero, A | 1 |
| Brosnihan, KB; Furberg, CD; Givens, DH; Herrington, DM; Kowalchuk, GJ; Reboussin, DM; Rogers, WJ; Sharp, PC; Shumaker, SA; Snyder, TE; Stuckey, TD; Waters, D | 1 |
| Kaunitz, AM | 1 |
| Colditz, GA; Grodstein, F; Manson, JE; Speizer, FE; Stampfer, MJ; Willett, WC | 1 |
| Naessen, T | 1 |
| Clarkson, TB | 1 |
| Stefanick, ML | 1 |
| Barnes, JF; Farish, E; Hart, DM; Rankin, M | 1 |
| Bilgin, O; Karadadaş, N; Sendağ, F; Terek, MC | 1 |
| Kenemans, P; Mijatovic, V; Neele, SJ; Netelenbos, JC; Smolders, RG; van Baal, WM; van der Mooren, MJ; Vogelvang, TE | 1 |
| Akerblom, M; Li, C; Samsioe, G | 1 |
| Bittner, V; Blumenthal, RS; Fong, J; Harris, F; Herrington, DM; Hunninghake, D; Levy, R; Lin, F; Schrott, HG; Vittinghoff, E | 1 |
| Ganz, P | 1 |
| Chi, IC; Hatcher, RA; Higgins, JE; Wilkens, LR | 1 |
| de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S | 1 |
| Keller, PJ | 1 |
| Barasolo, E; de Pauw, M; de Voogt, HJ; Lardennois, B; Pavone-Macaluso, M; Sylvester, R; Viggiano, G | 1 |
18 review(s) available for medroxyprogesterone acetate and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Topics: Cardiovascular Diseases; Estrogens; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2013 |
Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe?
Topics: Animals; Blood Coagulation; Brain; Breast Neoplasms; Cardiovascular Diseases; Cognition; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Postmenopause | 2014 |
Progestogen safety and tolerance in hormonal replacement therapy.
Topics: Animals; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Menopause; Progestins; Risk | 2016 |
Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?
Topics: Animals; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Postmenopause; Progesterone; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?
Topics: Biometry; Cardiovascular Diseases; Coronary Disease; Data Collection; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Hip Fractures; Humans; Medroxyprogesterone Acetate; Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Risk | 2003 |
Alternative hormone replacement regimens: is there a need for further clinical trials?
Topics: Administration, Cutaneous; Administration, Oral; Cardiovascular Diseases; Carotid Artery Diseases; Coronary Disease; Estradiol; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Randomized Controlled Trials as Topic; Risk; Treatment Outcome | 2003 |
Hormone replacement therapy update: who should we be prescribing this to now?
Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Hot Flashes; Humans; Medroxyprogesterone Acetate; Practice Guidelines as Topic; Practice Patterns, Physicians'; Time Factors; Women's Health | 2003 |
[Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland].
Topics: Adult; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Contraceptive Agents, Female; Family Planning Services; Female; Humans; Injections; Medroxyprogesterone Acetate; Poland; Pregnancy; Weight Gain; Women's Health | 2003 |
Considerations in the choice of oral vs. transdermal hormone therapy: a review.
Topics: Administration, Cutaneous; Administration, Oral; Cardiovascular Diseases; Chemistry, Pharmaceutical; Contraceptive Agents, Female; Estradiol; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Patient Care Planning; Postmenopause; Risk Factors | 2004 |
HRT Reconsidered: What should you tell patients about it now?
Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Nurses; Patient Education as Topic; Postmenopause; Risk Factors; Stroke | 2004 |
[Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate].
Topics: Cardiovascular Diseases; Cause of Death; Climacteric; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Randomized Controlled Trials as Topic | 2004 |
Depot medroxyprogesterone acetate contraception in women with medical problems.
Topics: Cardiovascular Diseases; Contraceptive Agents, Female; Delayed-Action Preparations; Diabetes Mellitus; Epilepsy; Female; Humans; Lupus Erythematosus, Systemic; Medroxyprogesterone Acetate; Pregnancy; Smoking | 1996 |
Oral contraception: current use and attitudes.
Topics: Breast Neoplasms; Cardiovascular Diseases; Condoms; Contraception; Contraceptives, Oral, Hormonal; Contraceptives, Oral, Synthetic; Female; Health Knowledge, Attitudes, Practice; Health Personnel; Humans; Intrauterine Devices; Levonorgestrel; Male; Mass Media; Medroxyprogesterone Acetate | 1999 |
Injectable contraception. New and existing options.
Topics: Affect; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Contraceptive Agents, Female; Estradiol; Female; History, 20th Century; Humans; Injections; Medroxyprogesterone Acetate; Pregnancy; Risk Factors; Weight Gain | 2000 |
Progestogens and cardiovascular disease. A critical review.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Disease Progression; Estrogens; Female; Hormone Replacement Therapy; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins, LDL; Medroxyprogesterone Acetate; Progesterone Congeners; Progestins | 1999 |
Estrogen, progestogens and cardiovascular risk.
Topics: Aged; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Contraceptives, Oral; Drug Administration Schedule; Drug Therapy, Combination; Estrogens; Female; Hormone Replacement Therapy; Humans; Lipoproteins, HDL; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone; Progesterone Congeners; Progestins; Weight Gain | 1999 |
Vasomotor and vascular effects of hormone replacement therapy.
Topics: Animals; Brachial Artery; Cardiovascular Diseases; Clinical Trials as Topic; Endothelium, Vascular; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pulsatile Flow; Selective Estrogen Receptor Modulators; Vasodilation | 2002 |
[Hormonal contraception using depot preparations].
Topics: Abnormalities, Drug-Induced; Blood Coagulation; Carbohydrate Metabolism; Cardiovascular Diseases; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Levonorgestrel; Liver; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasms; Norethindrone; Norgestrel; Pregnancy; Risk | 1986 |
38 trial(s) available for medroxyprogesterone acetate and Cardiovascular Diseases
| Article | Year |
|---|---|
Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hypertension; Hysterectomy; Medroxyprogesterone Acetate; Metabolic Syndrome; Middle Aged; Odds Ratio; Placebos; Postmenopause; Risk Factors; Women's Health | 2013 |
A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review o
Topics: Administration, Cutaneous; Adolescent; Adult; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Drug Therapy, Combination; Estradiol; Female; Hormone Replacement Therapy; Humans; Lipid Metabolism; Medroxyprogesterone Acetate; Primary Ovarian Insufficiency; Progesterone; Risk Factors; Treatment Outcome; Young Adult | 2013 |
[Analysis of the effects on menopausal symptoms, quality of Life, and cardiovascular risk factors of five different therapy in women at early stage of menopause].
Topics: Cardiovascular Diseases; Estradiol; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Menopause; Perimenopause; Progesterone; Quality of Life; Risk Factors | 2016 |
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial.
Topics: Aged; Calcium Carbonate; Calcium, Dietary; Cardiovascular Diseases; Cholecalciferol; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Prospective Studies; Risk Factors; Vitamins; Women's Health | 2017 |
The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
Topics: Blood Pressure; Body Composition; C-Peptide; Cardiovascular Diseases; Drug Therapy, Combination; Estrogen Receptor Modulators; Estrogens, Conjugated (USP); Female; Fibrinolysis; Humans; Medroxyprogesterone Acetate; Metabolic Syndrome; Middle Aged; Norpregnenes; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides | 2008 |
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
Topics: Adult; alpha-2-Antiplasmin; Antigens; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Combinations; Dydrogesterone; Endothelin-1; Estradiol; Estrogen Replacement Therapy; Factor VII; Female; Fibrinogen; Fibrinolysin; Homocysteine; Humans; Insulin-Like Growth Factor I; Medroxyprogesterone Acetate; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Risk Factors; Time Factors; Tissue Plasminogen Activator | 2009 |
Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy.
Topics: Adipose Tissue; Adult; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Hypertension; Hysterectomy; Inflammation Mediators; Lipids; Lipoproteins; Medroxyprogesterone Acetate; Metabolic Syndrome; Middle Aged; Ovariectomy; Progestins; Risk Factors; Serum Albumin | 2010 |
Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy.
Topics: Administration, Cutaneous; Administration, Oral; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Sex Hormone-Binding Globulin | 2010 |
Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Contraceptive Agents, Female; Female; Humans; Insulin Resistance; Medroxyprogesterone Acetate; Obesity; Pregnancy; Prospective Studies; Risk Factors; Young Adult | 2012 |
Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes.
Topics: Administration, Oral; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Intercellular Adhesion Molecule-1; Interleukin-6; Leukocyte Count; Linear Models; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Risk Factors; Statistics, Nonparametric; Vascular Cell Adhesion Molecule-1 | 2002 |
Menopausal symptoms in older women and the effects of treatment with hormone therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Confidence Intervals; Evaluation Studies as Topic; Female; Hormone Replacement Therapy; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Patient Satisfaction; Probability; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome | 2002 |
Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial.
Topics: Aged; Androgen Antagonists; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Postmenopause; Progesterone Congeners; Triglycerides | 2003 |
Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Antithrombin III; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cross-Over Studies; Double-Blind Method; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Progesterone; Triglycerides; Vasodilation | 2003 |
Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem and Mesigyna) and one oral contraceptive (Ortho-Novum 1/35) on coagulation and fibrinolysis.
Topics: Adolescent; Adult; Antithrombins; Blood Coagulation; Cardiovascular Diseases; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Drug Combinations; Estradiol; Factor VII; Factor X; Female; Fibrinogen; Fibrinolysis; Hemoglobins; Humans; Injections; Medroxyprogesterone Acetate; Mestranol; Norethindrone; Partial Thromboplastin Time; Plasminogen; Plasminogen Inactivators; Platelet Count; Protein C; Prothrombin | 2003 |
Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Topics: Antithrombin III; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dydrogesterone; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Prospective Studies; Prothrombin Time; Risk Factors; Triglycerides | 2004 |
Do lipid profiles of postmenopausal women under oral hormone replacement therapy remain stable or reveal a multiphasic course in time?
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipids; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Postmenopause; Triglycerides | 2004 |
Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.
Topics: Aged; Brachial Artery; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Endothelin-1; Endothelium, Vascular; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Nitrates; Nitrites; Postmenopause; Pulsatile Flow; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Vasodilation | 2004 |
The effect of hormone therapy on plasma homocysteine levels: a randomized clinical trial.
Topics: Adult; Cardiovascular Diseases; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Homocysteine; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Prospective Studies; Treatment Outcome | 2005 |
Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Topics: Blood Glucose; Cardiovascular Diseases; Desogestrel; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Postmenopause; Progestins; Risk Factors | 2005 |
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
Topics: Age Factors; Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Models, Statistical; Postmenopause; Risk; Time Factors | 2007 |
Effects of postmenopausal hormone replacement therapy on body fat composition.
Topics: Abdominal Fat; Administration, Cutaneous; Administration, Oral; Adult; Body Fat Distribution; Body Weight; Cardiovascular Diseases; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Risk Factors; Waist-Hip Ratio | 2007 |
Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.
Topics: Asia; Asian People; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Prospective Studies; Severity of Illness Index; Treatment Outcome; Triglycerides; Women's Health | 2007 |
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Biomarkers; Blood Pressure; Brachial Artery; C-Reactive Protein; Cardiovascular Diseases; Contraceptive Agents, Female; Drug Interactions; Endothelium, Vascular; Estradiol; Estrogens; Female; Gonadotropin-Releasing Hormone; Heart Rate; Homocysteine; Hormone Antagonists; Humans; Injections, Subcutaneous; Lipids; Medroxyprogesterone Acetate; Oligopeptides; Reproducibility of Results; Vasodilation | 2008 |
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasms; Risk Assessment | 2008 |
Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Topics: Adult; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Lipids; Lipoproteins; Medroxyprogesterone Acetate; Nigeria; Norgestrel; Risk Factors | 1993 |
Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
Topics: Administration, Cutaneous; Administration, Oral; Cardiovascular Diseases; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipoprotein(a); Lipoproteins, HDL; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Progesterone Congeners; Risk Factors | 1996 |
Metabolic effect of two hormonal preparations in postmenopausal women.
Topics: Angiotensinogen; Blood Coagulation Factors; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Climacteric; Cyproterone Acetate; Energy Metabolism; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Gonadal Steroid Hormones; Humans; Medroxyprogesterone Acetate; Middle Aged; Renin; Risk Factors | 1997 |
Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.
Topics: Aged; Cardiovascular Diseases; Cross-Sectional Studies; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipoprotein(a); Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone; Progesterone Congeners; Risk Factors; Treatment Outcome | 1998 |
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Topics: Aged; Analysis of Variance; Blood Coagulation Factors; Cardiovascular Diseases; Double-Blind Method; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Piperidines; Postmenopause; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Risk Factors | 1998 |
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.
Topics: Antigens; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; E-Selectin; Estrogens, Conjugated (USP); Factor VIII; Female; Hormone Replacement Therapy; Humans; Inflammation; Lipids; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone; Risk Factors; Smoking; Treatment Outcome; von Willebrand Factor | 1999 |
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Triglycerides | 2000 |
A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Nitrates; Nitrites; Norpregnenes; Oxidation-Reduction; Progesterone Congeners; Risk Factors; Time Factors; Treatment Outcome; Triglycerides; United Kingdom; Women's Health | 2002 |
Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
Topics: Administration, Cutaneous; Administration, Oral; Cardiovascular Diseases; Carotid Artery, Internal; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Progesterone Congeners; Prospective Studies; Pulsatile Flow | 2001 |
A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
Topics: Cardiovascular Diseases; Double-Blind Method; Estrogens, Conjugated (USP); Female; Homocysteine; Hormone Replacement Therapy; Humans; Lipoprotein(a); Medroxyprogesterone Acetate; Middle Aged; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2002 |
Electrocardiogram pattern in hypercholesterolemic women: the influence of hormone replacement therapy.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Electrocardiography; Estradiol; Estrogen Replacement Therapy; Female; Humans; Hypercholesterolemia; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Premenopause | 1998 |
Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).
Topics: Aged; Cardiovascular Diseases; Coronary Disease; Drug Interactions; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medroxyprogesterone Acetate; Myocardial Infarction; Postmenopause; Thromboembolism | 2002 |
Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer tria
Topics: Aged; Body Weight; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Estramustine; Europe; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Nitrogen Mustard Compounds; Prostatic Neoplasms; Random Allocation; Time Factors | 1986 |
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological
Topics: Aged; Bone Neoplasms; Carcinoma; Cardiovascular Diseases; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Europe; Follow-Up Studies; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prostatic Neoplasms; Random Allocation | 1986 |
56 other study(ies) available for medroxyprogesterone acetate and Cardiovascular Diseases
| Article | Year |
|---|---|
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials.
Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Gallbladder Diseases; Humans; Incidence; Intention to Treat Analysis; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; United States | 2020 |
Menopausal hormone therapy for primary prevention: why the USPSTF is wrong.
Topics: Breast Neoplasms; Cardiovascular Diseases; Chronic Disease; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Postmenopause; Primary Prevention; Risk Factors; Time Factors; United States; Women's Health | 2017 |
Hormone Therapy Use and Risk of Chronic Disease in the Nurses' Health Study: A Comparative Analysis With the Women's Health Initiative.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Chronic Disease; Comparative Effectiveness Research; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Neoplasms; Postmenopause; Risk Factors; State Medicine; Time Factors; Women's Health | 2017 |
Subclinical cardiovascular disease parameters after one year in new users of depot medroxyprogesterone acetate compared to copper-IUD.
Topics: Adiponectin; Adolescent; Adult; Body Composition; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Carotid Intima-Media Thickness; Contraceptive Agents, Female; Female; Humans; Interleukin-6; Intrauterine Devices, Copper; Leptin; Lipids; Liver Function Tests; Medroxyprogesterone Acetate; Prospective Studies; Tumor Necrosis Factor-alpha; Young Adult | 2018 |
Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women.
Topics: Analysis of Variance; Antioxidants; Cardiovascular Diseases; Chromans; Estrogens; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Lipoproteins, LDL; Medroxyprogesterone Acetate; Middle Aged; Oxidation-Reduction; Postmenopause; Probucol; Progestins; Quercetin; Resveratrol; Thiobarbituric Acid Reactive Substances; Treatment Outcome; Vitamin E; Wine | 2018 |
What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?
Topics: Administration, Cutaneous; Administration, Oral; Adult; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Progesterone; Randomized Controlled Trials as Topic; Risk Assessment; Venous Thromboembolism; Women's Health | 2014 |
Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate.
Topics: Adult; Cardiovascular Diseases; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Young Adult | 2016 |
Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).
Topics: Aged; Cardiovascular Diseases; Chest Pain; Contraceptive Agents, Female; Diabetes Mellitus; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hospitalization; Humans; Hypertension; Medroxyprogesterone Acetate; Middle Aged; Myocardial Revascularization; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk | 2008 |
Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
Topics: Adolescent; Adult; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Endothelium, Vascular; Female; Heart Rate; Humans; Lipids; Medroxyprogesterone Acetate; Regional Blood Flow; Risk Factors; Waist Circumference; Young Adult | 2009 |
Lung cancer and hormone replacement therapy.
Topics: Age Factors; Cardiovascular Diseases; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Incidence; Lung Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Randomized Controlled Trials as Topic; Risk | 2010 |
Transdermal estradiol and lipid profile: effects on a specific group of Brazilian postmenopausal women.
Topics: Administration, Cutaneous; Adult; Biomarkers; Brazil; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Follicle Stimulating Hormone; gamma-Glutamyltransferase; Gels; Humans; Lipid Metabolism; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Prospective Studies | 2009 |
Contraceptive options for women in selected circumstances.
Topics: Adolescent; Adult; Anemia; Breast Diseases; Cardiovascular Diseases; Condoms; Contraception; Contraceptive Agents, Female; Contraindications; Desogestrel; Diabetes Mellitus; Drug Combinations; Drug Implants; Epilepsy; Ethinyl Estradiol; Female; Heart Valve Diseases; Humans; Hypertension; Inflammatory Bowel Diseases; Injections; Intrauterine Devices; Levonorgestrel; Liver Diseases; Lupus Erythematosus, Systemic; Medroxyprogesterone Acetate; Migraine Disorders; Norethindrone; Norgestrel; Obesity; Patient Preference; Pregnancy; Progestins; Stroke; Young Adult | 2010 |
Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2010 |
Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2010 |
Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2010 |
Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Contraceptive Agents, Female; Female; Humans; Lipid Metabolism; Medroxyprogesterone Acetate; Nepal; Risk Factors; Triglycerides | 2011 |
Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Autoantibodies; Autoimmune Diseases; Cardiovascular Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Epitopes; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lipase; Lipoprotein Lipase; Lipoproteins, LDL; Medroxyprogesterone Acetate; Menopause; Middle Aged; Oxidation-Reduction; Oxidative Stress | 2011 |
Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women.
Topics: Aged; Asian People; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Risk Assessment; Taiwan | 2012 |
Women's health. The vanishing promises of hormone replacement.
Topics: Breast Neoplasms; Cardiovascular Diseases; Colorectal Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Menopause; Postmenopause; Pulmonary Embolism; Randomized Controlled Trials as Topic; Risk Factors; Selection Bias; Time Factors | 2002 |
Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey.
Topics: Administration, Oral; Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cross-Sectional Studies; Delayed-Action Preparations; Female; Health Surveys; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Lipoproteins; Lynestrenol; Medroxyprogesterone Acetate; Norethindrone; Norway; Progestins; Risk Factors; Triglycerides | 2002 |
Depo-Provera contraceptive may increase risk of cardiovascular disease.
Topics: Cardiovascular Diseases; Contraceptive Agents, Female; Female; Humans; Medroxyprogesterone Acetate | 2002 |
The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
Topics: Age Factors; Aged; Breast Neoplasms; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Women's Health | 2002 |
Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.
Topics: Administration, Cutaneous; Administration, Oral; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Estradiol; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Women's Health | 2002 |
The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women.
Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Evidence-Based Medicine; Female; Humans; Informed Consent; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Patient Selection; Postmenopause; Risk; Risk Factors; Women's Health | 2002 |
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Risk; Simvastatin | 2002 |
NIH workshop tries to create consensus on HRT use.
Topics: Age Factors; Breast Neoplasms; Cardiovascular Diseases; Consensus Development Conferences, NIH as Topic; Coronary Disease; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Randomized Controlled Trials as Topic; Risk; United Kingdom; United States; United States Food and Drug Administration | 2003 |
The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice.
Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone Congeners; Randomized Controlled Trials as Topic; Risk | 2003 |
Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women.
Topics: Adult; Cardiovascular Diseases; Complement C3; Complement C4; Contraceptive Agents, Female; Cross-Sectional Studies; Estradiol; Estrogen Replacement Therapy; Female; Humans; Immune System; Immunoglobulin G; Immunoglobulin M; Medroxyprogesterone Acetate; Middle Aged; Risk Factors | 2003 |
Are pharmacological considerations of relevance in hormone replacement therapy for prevention of chronic disease?
Topics: Cardiovascular Diseases; Chemistry, Pharmaceutical; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Randomized Controlled Trials as Topic | 2003 |
Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Biotransformation; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gene Expression Profiling; Genes, p53; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Paclitaxel; Pharmacogenetics; Tamoxifen; Trastuzumab | 2004 |
[Hormone replacement therapy and the risk of developing breast cancer].
Topics: Breast Neoplasms; Cardiovascular Diseases; Climacteric; Endometrial Neoplasms; Estrogens, Conjugated (USP); Ethinyl Estradiol; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment | 2004 |
[Postmenopausal hormone therapy after WHI and HERS].
Topics: Aged; Cardiovascular Diseases; Climacteric; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Treatment Failure | 2004 |
Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients.
Topics: Administration, Cutaneous; Blood Viscosity; Body Mass Index; Cardiovascular Diseases; Endometrium; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Pulsatile Flow; Risk Factors; Thromboxane B2; Triglycerides; Ultrasonography, Doppler, Color; Urinary Bladder; Vascular Resistance | 2004 |
Invited commentary: how far can epidemiologists get with statistical adjustment?
Topics: Aged; Bias; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Socioeconomic Factors; United States | 2005 |
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
Topics: Aged; Bias; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Observation; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Research Design; Socioeconomic Factors; Time Factors; United States | 2005 |
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
Topics: Aged; Bias; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Observation; Postmenopause; Progestins; Proportional Hazards Models; Randomized Controlled Trials as Topic; United States; Women's Health | 2006 |
Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial".
Topics: Aged; Bias; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Observation; Postmenopause; Randomized Controlled Trials as Topic; Research Design; Socioeconomic Factors; Time Factors; United States | 2006 |
Women's Health Initiative: not over yet. The largest study of women's health has raised at least as many questions as it has answered. Stay tuned.
Topics: Aged; Breast Neoplasms; Calcium, Dietary; Cardiovascular Diseases; Colonic Neoplasms; Diet, Fat-Restricted; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Women's Health | 2006 |
The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Metabolic Syndrome; Middle Aged; Neoplasms; Obesity; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Women's Health | 2006 |
Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies.
Topics: Aged; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Thromboembolism; Time Factors; Women's Health | 2006 |
High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
Topics: Administration, Cutaneous; Administration, Oral; Analysis of Variance; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Drug Administration Routes; Estradiol; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Inflammation; Intrauterine Devices, Medicated; Levonorgestrel; Lipids; Medroxyprogesterone Acetate; Menopause; Middle Aged; Risk Factors | 2007 |
New information about hormone therapy and cardiovascular disease prevention in women.
Topics: Adult; Age Factors; Aged; American Heart Association; Cardiovascular Diseases; Drug Combinations; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Guidelines as Topic; Humans; Life Style; Medroxyprogesterone Acetate; Middle Aged; Risk Factors; United States | 2007 |
Postmenopausal hormone replacement therapy and plasma lipoproteins.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Double-Blind Method; Drug Combinations; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Norethindrone; Norethindrone Acetate; Norgestrel; Postmenopause; Progesterone Congeners; Progestins; Randomized Controlled Trials as Topic; Risk Factors | 1995 |
Hormonal contraception. ACOG Technical bulletin. Number 198-October 1994 (replaces No. 106, July 1987) American College of Obstetricians and Gynecologists.
Topics: Breast Neoplasms; Cardiovascular Diseases; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Contraceptives, Postcoital; Female; Humans; Levonorgestrel; Liver Neoplasms; Medroxyprogesterone Acetate; Risk Factors; Uterine Cervical Neoplasms | 1995 |
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.
Topics: Apolipoproteins; Blood Coagulation Factors; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Risk Factors | 1993 |
An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins.
Topics: Adult; Apolipoproteins; Arteriosclerosis; Biomarkers; Cardiovascular Diseases; Cholesterol; Drug Administration Schedule; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Follicle Stimulating Hormone; Hong Kong; Humans; Lipoprotein(a); Lipoproteins; Longitudinal Studies; Luteinizing Hormone; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Risk Factors; Triglycerides | 1996 |
The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Body Composition; Carbohydrate Metabolism; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens; Female; Glycation End Products, Advanced; Horses; Macaca fascicularis; Medroxyprogesterone Acetate; Ovariectomy; Postmenopause; Postoperative Period; Risk Factors | 1996 |
Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women.
Topics: Blood Coagulation Factors; Cardiovascular Diseases; Electrocardiography; Endothelin-1; Estradiol; Estrogen Replacement Therapy; Female; Hemostasis; Humans; Lipoproteins; Longitudinal Studies; Medroxyprogesterone Acetate; Middle Aged; Platelet Aggregation; Postmenopause; Prospective Studies; Risk Factors; Ventricular Function, Left | 1998 |
Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Humans; Hypertension; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone Congeners; Risk Factors; Time Factors | 1998 |
Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone.
Topics: Adult; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone; Progesterone Congeners; Prospective Studies | 1998 |
Bhathena RK, Anklesaria BS, Ganatra AM, Pinto R. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins. Br J Clin Pharmacol 1998 Feb; 45 (2): 170-172.
Topics: Administration, Cutaneous; Cardiovascular Diseases; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Lipoproteins; Medroxyprogesterone Acetate; Patient Compliance; Progesterone Congeners; Randomized Controlled Trials as Topic; Research Design | 1998 |
[Influence of the presence of hot flashes during menopause on the metabolism of nitric oxide. Effects of hormonal replacement treatment].
Topics: Adult; Analysis of Variance; Antioxidants; Bilirubin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Estradiol; Estrogen Replacement Therapy; Female; Follow-Up Studies; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Oxidative Stress; Progesterone Congeners; Risk Factors; Serum Albumin; Time Factors; Triglycerides | 2000 |
[Hot flashes, menopause, nitric oxide and hormone replacement therapy: "one for all and all for one"].
Topics: Adult; Animals; Antioxidants; Cardiovascular Diseases; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Postmenopause; Pregnancy; Progesterone Congeners; Risk Factors; Time Factors | 2000 |
A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Prospective Studies; Regression Analysis; Risk Factors; Stroke | 2000 |
The Heart and Estrogen/Progestin Replacement Study (HERS) in perspective--results not very surprising.
Topics: Aged; Arteriosclerosis; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone Congeners; Randomized Controlled Trials as Topic; Reproducibility of Results; Survival Analysis | 2000 |
Hospitalizations among black women using contraceptives.
Topics: Adolescent; Adult; Age Factors; Black or African American; Breast Neoplasms; Carcinoma in Situ; Cardiovascular Diseases; Child; Contraceptives, Oral; Female; Georgia; Hospitalization; Humans; Intrauterine Devices; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Pelvic Inflammatory Disease; Pregnancy; Pregnancy, Ectopic; Risk; Time Factors; Uterine Cervical Neoplasms | 1985 |